WuXi XDC Cayman Inc. (2268.HK)
- Previous Close
38.600 - Open
38.950 - Bid 38.550 x --
- Ask 38.600 x --
- Day's Range
38.350 - 39.900 - 52 Week Range
14.080 - 49.500 - Volume
4,706,078 - Avg. Volume
9,011,966 - Market Cap (intraday)
46.26B - Beta (5Y Monthly) --
- PE Ratio (TTM)
42.83 - EPS (TTM)
0.900 - Earnings Date Aug 20, 2025 - Aug 27, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
50.87
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. The company engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It provides international sales contracting, biologics discovery, development, and manufacturing services. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.
wuxixdc.com2,041
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 2268.HK
View MorePerformance Overview: 2268.HK
Trailing total returns as of 5/21/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2268.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2268.HK
View MoreValuation Measures
Market Cap
46.32B
Enterprise Value
42.55B
Trailing P/E
42.91
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.32
Price/Book (mrq)
6.44
Enterprise Value/Revenue
9.69
Enterprise Value/EBITDA
29.44
Financial Highlights
Profitability and Income Statement
Profit Margin
26.39%
Return on Assets (ttm)
7.19%
Return on Equity (ttm)
17.69%
Revenue (ttm)
4.05B
Net Income Avi to Common (ttm)
1.07B
Diluted EPS (ttm)
0.900
Balance Sheet and Cash Flow
Total Cash (mrq)
3.97B
Total Debt/Equity (mrq)
7.48%
Levered Free Cash Flow (ttm)
-982.7M